![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/08/2895636/0/en/Seniors-in-Metro-Vancouver-Invited-to-Participate-in-a-Clinical-Trial-Assessing-a-New-Immunomodulator-Designed-to-Restore-Immune-Function-in-the-Elderly.html
https://www.globenewswire.com/news-release/2024/06/06/2894608/0/en/Qu-Biologics-and-Foundation-Medicine-Collaborate-to-Impact-the-Care-of-Patients-with-Late-Stage-Colorectal-Cancer.html
https://www.globenewswire.com/news-release/2023/01/23/2593158/0/en/Dr-Matt-Cahill-Appointed-Chief-Operating-Officer-of-Qu-Biologics.html
https://www.globenewswire.com/news-release/2022/12/14/2573635/0/en/Qu-Biologics-and-Karolinska-Institute-Initiate-Important-New-Collaboration-to-Validate-Molecular-Mechanisms-of-Qu-Biologics-First-in-Class-Immunotherapy-Platform.html
https://www.globenewswire.com/news-release/2022/10/17/2535417/0/en/Qu-Biologics-to-Receive-Additional-Funding-to-Support-Innovative-New-Treatment-to-Restore-Innate-Immune-Function-in-the-Elderly.html
https://www.globenewswire.com/news-release/2022/09/26/2522488/0/en/Qu-Biologics-to-Launch-Phase-2B-Clinical-Trial-to-Assess-Reduction-of-Postoperative-Immune-Suppression-and-Disease-Progression-in-Patients-with-Late-Stage-Colorectal-Cancer.html
https://www.globenewswire.com/news-release/2022/07/20/2482669/0/en/Qu-Biologics-to-Receive-Additional-Funding-to-Launch-Clinical-Trial-for-the-Restoration-of-Innate-Immune-Function-in-the-Elderly-Following-Health-Canada-Go-Ahead.html
https://www.globenewswire.com/news-release/2022/03/21/2406630/0/en/Qu-Biologics-Closes-USD-12M-Equity-Financing.html
https://www.globenewswire.com/news-release/2021/07/13/2261913/0/en/Qu-Biologics-Phase-2-RESTORE-trial-data-presented-at-2021-European-Crohn-s-and-Colitis-Congress.html
https://www.globenewswire.com/news-release/2021/06/23/2251709/0/en/Qu-Biologics-Receives-Additional-Funding-to-Accelerate-Clinical-Development-of-Qu-s-First-in-Class-Immunotherapeutic-for-COVID-19-Prevention-and-Treatment.html